Benjamin Miller

Ceftolozane/Tazobactam Plus Metronidazole for Complicated Intra-abdominal Infections in an Era of Multidrug Resistance: Results From a Randomized, Double-Blind, Phase 3 Trial (ASPECT-cIAI)

Joseph S. Solomkin, Ellie Hershberger, Benjamin Miller et al. · Clinical Infectious Diseases · 2015 · 400 citations · Full text

Ceftolozane/tazobactam pharmacokinetic/pharmacodynamic‐derived dose justification for phase 3 studies in patients with nosocomial pneumonia

Alan Xiao, Benjamin Miller, Jennifer A. Huntington et al. · The Journal of Clinical Pharmacology · 2015 · 149 citations · Full text

Dose Justification, Elf Pk Study, Pharmacotherapy +17

Pharmacokinetics and Safety of Intravenous Ceftolozane-Tazobactam in Healthy Adult Subjects following Single and Multiple Ascending Doses

Benjamin Miller, Ellie Hershberger, David P. Benziger et al. · Antimicrobial Agents and Chemotherapy · 2012 · 117 citations · Full text

Mean Values, Healthy Adult Subjects, Pharmacotherapy +20

Efficacy of ceftolozane/tazobactam against urinary tract and intra-abdominal infections caused by ESBL-producing <i>Escherichia coli</i> and <i>Klebsiella pneumoniae</i> : a pooled analysis of Phase 3 clinical trials

Myra W. Popejoy, David L. Paterson, Daniel Cloutier et al. · Journal of Antimicrobial Chemotherapy · 2016 · 115 citations · Full text

Multicenter, Double-Blind, Randomized, Phase II Trial To Assess the Safety and Efficacy of Ceftolozane-Tazobactam plus Metronidazole Compared with Meropenem in Adult Patients with Complicated Intra-Abdominal Infections

Christopher Lucasti, Ellie Hershberger, Benjamin Miller et al. · Antimicrobial Agents and Chemotherapy · 2014 · 107 citations · Full text